A new RSV shot could help protect babies this winter—if they can get it in time

by

A RSV new therapy for infants, called nirsevimab, started shipping in September. By mid-October, demand for nirsevimab, sold under the brand name Beyfortus, had already outstripped supply, according to the pharmaceutical company Sanofi, which developed the drug with AstraZeneca.

Leave A Comment

Your email address will not be published. Required fields are marked *